



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/040,046	10/19/2001	John B. Taylor	396542	1834
7590		05/03/2010	EXAMINER	
Kenneth D Goetz Lathrop & Gage LC Suite 2800 2345 Grand Boulevard Kansas City, MO 64108			LEVY, NEIL S	
		ART UNIT	PAPER NUMBER	
		1615		
		MAIL DATE	DELIVERY MODE	
		05/03/2010	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/040,046	Applicant(s) TAYLOR, JOHN B.
	Examiner NEIL LEVY	Art Unit 1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
 - If no period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
 - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on 23 March 2010.
- 2a) This action is FINAL. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-14 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) 1-14 is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) Notice of References Cited (PTO-892)
 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
 3) Information Disclosure Statement(s) (PTO/SB/08)
 Paper No(s)/Mail Date _____
- 4) Interview Summary (PTO-413)
 Paper No(s)/Mail Date _____
- 5) Notice of Informal Patent Application
 6) Other: _____

DETAILED ACTION

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Defective Reissue Oath/Declaration, 37 CFR 1.175

This reissue was filed without a reissue oath.

The reissue oath/declaration filed 10/16/07 with this application is defective (see 37 CFR 1.175 and MPEP § 1414) because it is an "Assignee Oath" and not an "Inventor Oath". A broadening reissue application must be applied for by all of the inventors (patentees), that is, the original reissue oath or declaration must be signed by all of the inventors. See also MPEP § 1414.

Please consider using PTO/SB/51 (10-05) found on the U.S. PTO website.

Consent of Assignee to Reissue Lacking

This application is objected to under 37 CFR 1.172(a) as lacking the written consent of all assignees owning an undivided interest in the patent. The consent of the assignee must be in compliance with 37 CFR 1.172. See MPEP § 1410.01. A proper assent of the assignee in compliance with 37 CFR 1.172 and 3.73 is required in reply to this Office action.

Rejection, Defective Reissue Oath or Declaration

Claims 1-14 are rejected as being based upon a defective reissue [2] under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175

Rejection, 35 U.S.C. 251, Broadened Claims Filed by Assignee

Claims 3-14 are rejected under 35 U.S.C. 251 as being improperly broadened in a reissue application made and sworn to by the assignee and not the patentee. Here the added method claims are broader than the issued composition claims 1-2. A claim is broader in scope than the original claims if it contains within its scope any conceivable product or process which would not have infringed the original patent. A claim is broadened if it is broader in any one respect even though it may be narrower in other respects

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 4& 10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

These claims are redundant. Claim 1 requires 0.25 to 5%.

Claim1 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

If the second formula is, as claimed, a salt, then one of R1 and R3 must be K. This is not claimed. Please amend.

If not amended, applicant is using “salt” in a non-accepted manner.

Claim 1 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant changed alkynyl to alkynyl. The first should be bracketed; the second, underlined.

Claim 2 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in e relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

There is no basis for a pH and a minimum of 20 nM. The new matter should be removed.

Claims 6-8 and 12-14 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

No preparation is disclosed as is claimed. Item C at Column 4 of the patent states that solutions of the compounds are mixed. No KOH is evident, as the solution of the compounds at A. and B. are the claimed phosphonates and water, and phosphates and water.

Claim Rejections - 35 USC § 102

Claims 1 is rejected under 35 U.S.C. 102(b) as being anticipated by Spraker-4350770.

(a) Spraker discloses a basic salt solution in Example I (column68) which defines a composition that fully meets the limitations of the instant claims.

The monobasic potassium phosphate (K₂HPO₄) is present at a concentration of 52 mM. This same basic salt solution also contains dibasic phosphite (KH₂PO₃) at a concentration of 25 mM. These concentrations of potassium phosphite and potassium phosphate fall within the range of "about 20 ml~to about 5% v/v" in claim1. The open language of "comprising" permits the additional components of the Spraker

compositions which include ammonium chloride, ammonium sulfate, magnesium sulfate, and ammonium nitrate. The intended use as a fertilizer is interpreted to mean that the fertilizer cannot be toxic to plants and stimulates plant growth. The growth stimulating activities are considered to be an inherent property of any composition containing all of the required ingredients at the stated concentrations.

See *In re Fitzgerald*, 205 USPQ 594 (CCPA 1980). See also *In re May*, 197 USPQ 601,607 (CCPA 1978).

The instantly claimed fertilizers are anticipated by the Spraker salt solution (col. 10, lines 60 - 68) because the Spraker salt solution contains potassium phosphite and potassium phosphate at a concentration of between about 20mM and 5% vol/vol. The fungicidal activity and plant growth stimulating activities are deemed to be an inherent characteristic of any composition which meets the concentration limits of phosphite and phosphate, the molar ratio of phosphite to phosphate in the claims, and which lacks any toxic effects on plants generally.

Claim Rejections - 35 USC § 103

Claims 1,2, STAND rejected under 35 U.S.C. 103(a) as being unpatentable over Spraker- 4350770.

Response to Arguments

Applicant's arguments filed 3/23/2010 have been fully considered but they are not persuasive. Applicant argues SPRAKER is basic, and not for foliar spray fungicidal effects.

Claimed is a composition, its use obvious to test for to determine optimal concentrations.

Example I meets the instant claim 1 requirement. SPRAKER shows pH as low as 5.5- (col.9, lines 13-17) that meets the instant claim 5 to 7 ,and the functional advantage as a foliar spray is not claimed. One in the art would find it obvious to test to determine effective amounts.

Applicant should show the range of concentrations, inclusive of pH 5.5-7.0, would not encompass the instant claimed amounts of at least 20nM.

It would have been well within the skill of one of ordinary skill in the art to have applied the combination of potassium phosphonate salts and potassium phosphate salts to plants with the expectation that said combination would have been effective in promoting the growth of plants. Further, one of ordinary skill in the art would have been motivated to vary the amount or concentration of said salts, including the amounts or concentrations falling within the claimed values, as desired, depending on the host plant and the climate conditions. This would have simply been routine experimentation by the artisan to find the optimal concentration of phosphite and phosphate. Therefore, the

claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention was made, with adjustment of pH as necessary to maintain a solution of the composition

Claims 1, 6 & 12 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Fenn et al '84 & Dolan et al '88, with evidence exemplified by Barlet-5070083.

Claims 1, ,6& 12 STAND rejected under 35 U.S.C. 103(a) as being unpatentable over Barlet 5070083,Ducret et al 4139616,Horriere et al 5169646, Lovatt 5514200, Vetanovetz et al 53905418 and Smillie et al '89.

Here, too, we find one in the art would be aware of these references & straight forward testing would enable one to achieve desired effects, in accord with standard practice in the horticultural arts. These references, of record, teach the instant Phosphonate salts are well known, art recognized fungicides (Bartlet, Ducret & Horriere) while Lovatt & Vetanovetz likewise teach the Phosphates are well known, art recognized fertilizers. Smillie shows the effectiveness of phosphite salts are enhanced with phosphates (p 924 of Smillie).

It would have been obvious to a person of ordinary skill in the art at the time the invention was made desiring to utilize fungicidal control means on plants, to use any of art recognized means, modified as desired to increase stability, dispersibility, compatibility of ingredients, processing ease, decreased toxicity to handlers, increased

toxicity to fungus, & to provide added benefit;fertilizer & fungicide in one application.

The particular manner in which the compositions are made is not seen to be of patentable weight. Simple testing would enable one in the art to determine the optimal amounts needed , & is in the purview of the artisan to perform. See KSR V TELEFLEX @ 82 USPQ 2d @ 1385.

The amounts and proportions of each ingredient are result effective parameters chosen to obtain the desired effects. It would have been obvious to vary the form of each ingredient to optimize the effect desired, depending upon the particular species and application method of interest, reduction of toxicity, cost minimization, enhanced, and prolonged, or synergistic effects.

Applicant has not provided any objective evidence of criticality, nonobvious or unexpected results that the combination of the particular ingredients' or concentrations provides any greater or different level of prior art expectation as claimed, and the use of ingredient for the functionality for which they are known to be used is not basis for patentability.

The instant invention provides well known old art recognized compounds, with well known art recognized effects, applied by well known art recognized methods to achieve improved control as is well known in the art.

Applicant's arguments filed 3/23/2010 have been fully considered but they are not persuasive.

Applicant argues the SMILIE reference showed the opposite of the claimed invention, and preponderance of evidence favors phosphate inhibiting the phosphite enhancement. However, examiner finds SMILIE shows one must test the specific strain of plant of concern to determine optimum concentration of phosphate, if any, to add to an intended phosphite.

It would have been well within the skill of one of ordinary skill in the art to have applied the combination of potassium phosphonate salts and potassium phosphate salts to plants with the expectation that said combination would have been effective in promoting the growth of plants and controlling fungal infections. Further, one of ordinary skill in the art would have been motivated to vary the amount or concentration of said salts, including the amounts or concentrations falling within the claimed values, as desired, depending on the susceptibility of the fungus, the extent of disease, the host plant and the climate conditions. This would have simply been routine experimentation by the artisan to find the optimal concentration of phosphite and phosphate. Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references and clear motivation existed to combine the references.

Claim1,3-5,9-11 are rejected under 35 U.S.C. 103(a) as being unpatentable over Thyzy et al. (4,075,324) in view Reuveni et al. (J. Phytopathology, 141 : 337 - 346 1994), Reuveni et al. (Plant Pathology 44:31 - 39, 1995), Dunstan et al. (Physiol. Molec. Plant Path. 36:205 - 220, 1990), the Fenn Dissertation (1996), Walker (Fungic. Nematic. Tests, 1994), and the Fluid Fertilizer Manual (1995).

Thizy et al. disclose fungicidal compositions containing monopotassium phosphite (KH_2PO_3) and compositions containing potassium phosphite (K_2HPO_3) at column 1, lines 52 - 56 and column 2, lines 32 - 36. It is disclosed that the above fungicidal compositions are generally not applied to crops alone, but are applied in combination with other materials, such as support, which can be a mineral material which facilitates the application to the plant and can be solid or fluid (column 8, line 60 - column 9, line 15). It is also disclosed that the above fungicidal compositions can be mixed with other fungicidal, anti-mildew phosphorous derivatives (column 8, lines 44 - 46). It is further disclosed that 0.5 g/L of KH_2PO_3 (compound 4) or K_2HPO_3 (compound 5) applied to plants prior to infestation with *Plasmopara viticola* afforded total protection and that 1 g/L of the same (6.3 mM of K_2HPO_3 and 8.3 mM of KH_2PO_3) applied after infestation completely stopped the development of mildew on the plant (column 2, lines 31 - 38 and column 6, lines 31 - 68). Finally, Thizy et al. disclose that doses of from 0.01 to 5 g/L are generally suitable but that the doses may vary within wide limits depending on both the virulence of the fungus and upon the climate conditions (column 8, lines 55 - 59). 5 g/L of K_2HPO_3 is 32 mM. 5 g/L of KH_2PO_3 is 42 mM. Thizy et al. discloses

compositions of either potassium phosphite or potassium phosphate in the desired concentration range but fails to teach the specific combination of these two ingredients. Reuveni et al. (*J. Phytopathology*, 1994) disclose that K₂HPO₄ and KH₂PO₄ are each effective against the fungus *E. turicum* on corn and that phosphates have exhibited effectiveness against *P. sorghi* and *S. fuliginea* on maize and cucumbers, respectively, and are effective in enhancing the growth of plants (See entire document.) It is further taught that 100 mM of K₂HPO₄ or KH₂PO₄ was applied to said corn plants (page 339).

Finally, it is disclosed that phosphates are not only fungicides but also fertilizers (page 338). Reuveni et al. (*Plant Pathology*, 1995) disclose K₂HPO₄ and KH₂PO₄ are each effective against powdery mildew caused by *S. fuliginea* on cucumber and that phosphates have exhibited effectiveness against *E. turicum* and *P. sorghi* on maize and against various diseases in cucumber and are effective in stimulating plant growth (See entire document.). It is also disclosed that 25 mM of K₂HPO₄ or KH₂PO₄ was applied to said cucumber plants (page 31). Reuveni et al. teach that the properties of phosphates and potassium salts thereof make them appropriate for use as foliar fertilizers (page 31). The two Reuveni et al. references teach the effectiveness of potassium phosphate as a fungicide against several types of fungi at a concentration of

25 mM. However, there is no teaching of combining potassium phosphite and potassium phosphate into a single composition at the claimed concentration as an effective fungicide and fertilizer.

Dunstan et al. disclose that the active toxophore of fosetyl-AL is phosphonate produced by catabolism of fosetyl-AL in the plant (page 205). Additionally, it is taught that phosphonate supplied as the potassium salt (Foli-r-fos ®) provides as effective control of many pathogens as fosetyl-AL (page 205). Thus, Dunstan et al. emphasizes the effectiveness of phosphate ion as an antifungal agent but there is no teaching of the combination of potassium phosphite and potassium phosphate.

The cumulative teachings of Thizy et al., Reuveni et al. '94 and '95, and Dunstan disclose the effectiveness of potassium phosphite and potassium phosphates individually as possessing both fungicidal and fertilizer activities but do not teach the specific combination of these two ingredients in the stated concentrations. The Fenn dissertation (1986) provides the missing piece of the obviousness rejection by disclosing the combination of phosphite and phosphate ion in a single composition for the treatment of fungal infections. The Fenn dissertation further teaches that fosetyl-AL and phosphorus acid (H_3PO_3) (from which phosphate ions are derived) are effective fungicides in the presence of potassium phosphates (pages 63 - 72). It is further disclosed that the potential antagonistic effects of tissue phosphate levels on in vivo efficacy of phosphonate compounds have probably been over emphasized (page 72).

Additionally, it is taught in Fenn that in some cases disease control with H₃PO₃ in tomato seedlings inoculated with P. palmivora was enhanced when higher concentrations of phosphate were included in the treatments and that at some concentrations of H₃PO₃, inhibition of mycelial growth in vitro was greater at 45 mM than at 15 mM phosphate with P. capsici and P. parasitica var. nicotinanae (Ibid, pages 72 - 73).

Walker et all. also discloses that a combination of potassium dihydrogen orthophosphate (phosphate) and Foli-R-Fos 200 AC® (potassium phosphite), inhibited in vitro the growth of fungi and that the growth of Phytophthora cactorum, P. cinnamomi, P. citrophthora, P. megasperma and Pythium ultimum, and was subject to significant PO₃/PO₄ interactions.

The Fluid Fertilizer Manual discloses that higher crop yields can be maintained by application of mixtures of pesticides, such as fungicides, and fluid fertilizers which control fungi while fertilizing the crop (Ch. 6, Section I, page 6-1). It is disclosed that one of the advantages of fluid fertilizers is the ease of preparation of stable, uniform mixes of fluid fertilizer with chemicals than can be applied uniformly and that this advantage greatly facilitates the simultaneous application of fertilizer and pesticide (Ch. 6, Section 1, 1.2, page 6-2). It is taught that it is known to combine fluid fertilizer with fungicides (Ibid.) It is disclosed that the adoption of applying pesticides with fluid fertilizer is attributed to the savings of time, money and other resources, which is sound

agronomic management (*Ibid.*) It is taught that the combination of pesticide with fluid fertilizer has been shown to enhance crop growth synergistically because the presence of fertilizer makes possible quick, vigorous growth of the crop enabling the crop to more effectively compete with pests held in check by the pesticide, and/or the presence of the pesticides increases effective utilization of fertilizer (*Ibid.*) Finally, the Fluid Fertilizer Manual teaches that in some cases, applying fertilizer with pesticides will enhance the effectiveness of the pesticide on its target (*Ibid.*)

In summary, Thizy et al.; Reuveni et al. ('94 and '95), Dunstan et al. collectively teach that potassium phosphates and potassium phosphites are effective individually as fungicides against Ascomycetes fungi and as fertilizers in concentrations that fall within the claimed amounts. Additionally, Fenn and Walker each disclose a composition of both phosphite and phosphate ions which were used as antifungal agents. Fenn further discloses that in some cases fungal disease control with phosphite can be enhanced with 45 mM phosphate. Walker discloses a fungicidal composition containing at most

10 mM potassium phosphite and 10 mM potassium phosphate. The Fluid Fertilizer Manual teaches that there is sound basis generally for combining fertilizers with pesticides which includes fungicides.

The difference between the above prior art and the claimed invention is that the prior art does not expressly disclose a method of controlling fungus disease in plants *in vivo* by applying to the plants the claimed amount (about 20 mM to 5% vol/vol) of

potassium phosphonate salts in combination with potassium phosphate salts. However, the prior art amply suggests the same combination of the instant invention since the prior art discloses that the combination of potassium phosphonate and potassium phosphite salts exhibit in vitro activity against fungi (Fenn and Walker). The prior art further discloses that potassium phosphonates salts and potassium phosphites salts are each effective fungicides and fertilizers (Thizy et al., Reuveni et al. '94 and '95; Dunstan et al.). The combination of fertilizers and fungicides as a single product for application on to plants is an efficient agronomic strategy (Fluid Fertilizer Manual). As such it would have been well within the skill of one of ordinary skill in the art to have applied the combination of potassium phosphonate salts and potassium phosphate salts to plants with the expectation that said combination would have been effective in promoting the growth of plants and controlling fungal infections. Further, one of ordinary skill in the art would have been motivated to vary the amount or concentration of said salts, including the amounts or concentrations falling within the claimed values, as desired, depending on the susceptibility of the fungus, the extent of disease, the host plant and the climate conditions. This would have simply been routine experimentation by the artisan to find the optimal concentration of phosphite and phosphate.

Therefore, the claimed invention, as a whole, would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention was made, because every element of the invention has been collectively taught by the combined teachings of the references and clear motivation existed to combine the references.

Claims 1,2 rejected under 35 U.S.C. 103(a) as being unpatentable over Thyzy et al. (4,075,324.

Thyzy et al.-4,075,324; Reuveni et al. '94 ; Reuveni et al. '95 ; Dunstan et al.; Fenn Dissertation ; and Walker as set forth above, and further in view of Lovatt - 5,514,200.

As explained above, the combined references of Thyzy et al.; Reuveni et al. '94 Reuveni et al. '95 ; Dunstan et al ; Fenn Dissertation ; Walker; and The Fluid Fertilizer Manual render obvious fungicidal compositions comprising potassium phosphite and potassium phosphate at a concentration of about 20 mM to 5% vol/vol, or at least about 20 mM and a ratio of phosphite to phosphate ion of 0.001 to 1,000. The only substantial difference between the claimed compounds and instant claims is the inclusion of a pH limitation: "having a pH equal to or less than 7.0" or "having a pH of less than 7.0." The above references are primarily silent with regard to the desired pH of such solutions. However, Lovatt (5,514,200) discloses that a "foliage-acceptable pH for phosphorus

uptake usually ranges between about 5.0 to about 7.0 ..." Lovatt explains that "At higher pH, between about 7.0 to about 7.5 there is reduced uptake of nutrients, although generally there is no plant damage." See column 3, lines 26 - 33 and column 4, lines 19 - 32. Therefore, the person of skill in the art with the above references before him, would have found it obvious to have adjusted the pH of the fungicidal composition of potassium phosphite and potassium phosphate to either "less than 7.0" or to "equal to

or less than 7.0" in order to prevent any damage to the plant and to prevent any reduction in the uptake of phosphorus by the plant. For the same reasoning, it would have also been obvious to have applied these same compositions with an approximately neutral pH to plants in order to control fungal disease and promote plant growth at the same time. The artisan would have had a reasonable expectation of success in controlling fungal disease and in promoting plant growth because the prior art teaches that both potassium phosphite and potassium phosphate are recognized fertilizers and fungicides.

Double Patenting

Claims 1,3-14 STAND rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-12 of U.S. Patent No. US006509041B2 . Although the conflicting claims are not identical, they are not patentably distinct from each other because the patent claims encompasses the instant claims & would anticipate them.

Claims 1, 3-5,9-11 STAND rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim2,4,5 of U.S. Patent No. 5800837. Although the conflicting claims are not identical, they are not patentably distinct from each other because the patent claims encompass the instant

compositions, ratios, & concentrations, thus besides stimulating growth, the patent would inherently meet the instant claim to control fungus.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to NEIL LEVY whose telephone number is 571-272-0619. The examiner can normally be reached on Tuesday-Friday, 7 AM to 5:30 PM EST..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, ROBERT A. WAX can be reached on 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1615

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/NEIL LEVY/
Primary Examiner, Art Unit 1615

4/23/2010